Table 2 Summary of treatment effects: 1860 and LEAD-6 trials & long-term progression approach
Risk Factor | 1860 clinical trial* | LEAD-6 clinical trial¶ | Long-term progression | ||||||
|---|---|---|---|---|---|---|---|---|---|
Liraglutide (1.2 mg) | Sitagliptin (100 mg) | Liraglutide (1.8 mg) | Exenatide BID (10 μg) | All comparators | |||||
Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||
Change from baseline in HbA1c (%) | −1.24 | 1.04 | −0.90 | 1.04 | −1.12 | 1.22 | −0.79 | 1.22 | No HbA1c creep assumption |
Change from baseline in SBP (mm Hg) | −0.55 | 13.23 | −0.94 | 13.17 | −2.51 | 17.55 | −2.00 | 17.93 | UKPDS progression |
Change from baseline in total cholesterol (mmol/l) | −0.03 | 0.82 | −0.02 | 0.80 | −0.20 | 1.02 | −0.09 | 1.01 | Framingham progression |
Change from baseline in LDL (mmol/l) | 0.08 | 0.69 | 0.13 | 0.68 | −0.44 | 0.84 | −0.40 | 0.84 | Framingham progression |
Change from baseline in HDL (mmol/l) | 0.00 | 0.17 | 0.00 | 0.17 | −0.04 | 0.23 | −0.05 | 0.23 | Framingham progression |
Change from baseline in triglycerides (mmol/l) | −0.19 | 1.42 | −0.40 | 1.38 | −0.41 | 1.50 | −0.23 | 1.48 | Framingham progression |
Change from baseline in BMI (kg/m2) | −1.00 | 0.08 | −0.34 | 0.08 | −1.15 | 1.35 | −1.02 | 1.47 | Constant after returning to baseline |
Major hypoglycaemia (events per 100 patient-years) | 1.00 | 0.00 | 0.00 | 2.00 | 0.00# | ||||
Minor hypoglycaemia (events per 100 patient-years) | 17.80 | 10.60 | 193.20 | 260.00 | 128.70# | ||||